MiNK reports Q2 2023 net loss $6.2M; cash low at $10.6M; Phase 2 gastric trial planned

MiNK Therapeutics, Inc.

2023-Q2 EPS reported -$0.35

Six-month 2023 net loss $11.9M ($0.35/share) vs $13.9M ($0.41) in prior year period.
Cash $10.6M at June 30, 2023, down from $14.9M at March 31, 2023; Q2 cash used $4.1M.
Externally funded randomized Phase 2 trial in 2L gastric cancer planned at MSKCC; IND for MiNK-215 on track for 2024.
AgenT-797 showed 75% survival in COVID-19 ARDS patients vs 30% in-hospital controls; dosed up to 1B cells.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

MiNK Therapeutics, Inc. reported the second quarter 2023 results: net income Net loss for the six-months ended June 30, 2023 was $11.9 million, or $0.35 per share.

Period: the second quarter 2023
Net income: Net loss for the six-months ended June 30, 2023 was $11.9 million, or $0.35 per share
Result: reported results

Exact text from the filing

On August 10, 2023, MiNK Therapeutics, Inc. announced its financial results for the quarter ended June 30, 2023.

View on SEC.gov

Browse all earnings releases →

MiNK Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001171843-23-005189

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.